Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension

Background— Heterogeneity in response to treatment of pulmonary arterial hypertension (PAH) is a major challenge to improving outcome in this disease. Although vasodilator-responsive PAH (VR-PAH) accounts for a minority of cases, VR-PAH has a pronounced response to calcium channel blockers and better survival than vasodilator-nonresponsive PAH (VN-PAH). We hypothesized that VR-PAH has a different molecular cause from VN-PAH that can be detected in the peripheral blood. Methods and Results— Microarrays of cultured lymphocytes from VR-PAH and VN-PAH patients followed at Vanderbilt University were performed with quantitative polymerase chain reaction performed on peripheral blood for the 25 most different genes. We developed a decision tree to identify VR-PAH patients on the basis of the results with validation in a second VR-PAH cohort from the University of Chicago. We found broad differences in gene expression patterns on microarray analysis including cell-cell adhesion factors and cytoskeletal and rho-GTPase genes. Thirteen of 25 genes tested in whole blood were significantly different: EPDR1, DSG2, SCD5, P2RY5, MGAT5, RHOQ, UCHL1, ZNF652, RALGPS2, TPD52, MKNL1, RAPGEF2, and PIAS1. Seven decision trees were built with the use of expression levels of 2 genes as the primary genes: DSG2, a desmosomal cadherin involved in Wnt/&bgr;-catenin signaling, and RHOQ, which encodes a cytoskeletal protein involved in insulin-mediated signaling. These trees correctly identified 5 of 5 VR-PAH patients in the validation cohort. Conclusions— VR-PAH and VN-PAH can be differentiated with the use of RNA expression patterns in peripheral blood. These differences may reflect different molecular causes of the 2 PAH phenotypes. This biomarker methodology may identify PAH patients who have a favorable treatment response.

[1]  J. Newman,et al.  Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function , 2013, Pulmonary circulation.

[2]  Roderick C Deaño,et al.  Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. , 2013, JAMA internal medicine.

[3]  J. Newman,et al.  Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. , 2013, JACC. Heart failure.

[4]  D. Harrison,et al.  Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling , 2013, Pulmonary circulation.

[5]  L. Gleaves,et al.  A potential role for insulin resistance in experimental pulmonary hypertension , 2012, European Respiratory Journal.

[6]  J. Harral,et al.  Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[7]  S. Menon,et al.  Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression , 2011, Pulmonary circulation.

[8]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[9]  T. Rice,et al.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[11]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[12]  Marisa Wong Medina,et al.  Pharmacogenomic Discovery Using Cell-Based Models , 2009, Pharmacological Reviews.

[13]  H. Champion,et al.  Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography , 2009, International journal of clinical practice. Supplement.

[14]  J. Newman,et al.  Association of the metabolic syndrome with pulmonary venous hypertension. , 2009, Chest.

[15]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[16]  N. Weissmann,et al.  Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[17]  J. Cogan,et al.  Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance , 2008, BMC Medical Genomics.

[18]  H. Calkins,et al.  Mechanisms of Disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy , 2008, Nature Clinical Practice Cardiovascular Medicine.

[19]  G. Hansmann,et al.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.

[20]  M. Maitland,et al.  Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. , 2008, American journal of physiology. Heart and circulatory physiology.

[21]  Michael D. Schneider,et al.  Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. , 2006, The Journal of clinical investigation.

[22]  Hugh Calkins,et al.  DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, American journal of human genetics.

[23]  S. Archer,et al.  An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.

[24]  Eric W. Glissmeyer,et al.  Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension , 2006, Circulation.

[25]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[26]  G. Danieli,et al.  Mutations in Desmoglein-2 Gene Are Associated With Arrhythmogenic Right Ventricular Cardiomyopathy , 2006, Circulation.

[27]  D. Peterson,et al.  Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction , 2005, Circulation.

[28]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[29]  J. Pessin,et al.  Lipid Raft targeting of the TC10 amino terminal domain is responsible for disruption of adipocyte cortical actin. , 2003, Molecular biology of the cell.

[30]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[31]  B. Brundage,et al.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.

[32]  W. Chung,et al.  A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  J. Kartenbeck,et al.  Desmosomes and hemidesmosomes: constitutive molecular components. , 1990, Annual review of cell biology.